Autolus Therapeutics plc (AUTL)
| Market Cap | 322.06M -8.3% |
| Revenue (ttm) | 137.43M +168.8% |
| Net Income | -256.13M |
| EPS | -0.96 |
| Shares Out | 266.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 776,690 |
| Open | 1.210 |
| Previous Close | 1.235 |
| Day's Range | 1.185 - 1.240 |
| 52-Week Range | 1.120 - 2.580 |
| Beta | 2.35 |
| Analysts | Strong Buy |
| Price Target | 8.36 (+591.16%) |
| Earnings Date | Nov 10, 2026 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph... [Read more]
Financial Performance
In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $8.36, which is an increase of 591.16% from the latest price.
News
Autolus presents longer-term CARLYSLE lupus data at rheumatology meeting
Autolus Therapeutics (AUTL) announced longer-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosu...
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline In 15 patients evaluable for safety, obe-cel wa...
Autolus Therapeutics reports Q3 EPS (21c), consensus (17c)
Reports Q3 revenue $41.24M, consensus $40.03M. “We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain posi...
Autolus Therapeutics backs FY26 revenue view $150M, consensus $149.78M
The company said, “Autolus now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding the upper end of $150 million from the prior guidance. Based on current…
Autolus Therapeutics Earnings Call Transcript: Q3 2026
Q3 AUCATZYL revenue rose 95% YoY, and FY 2026 guidance increased to at least $150 million. Gross margin reached 57%; cash runway is projected into Q2 2028, assuming the second credit tranche.
Autolus Therapeutics Earnings release: Q3 2026
Autolus Therapeutics released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Autolus Therapeutics Slides: Q3 2026
Autolus Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
Autolus Therapeutics Quarterly report: Q3 2026
Autolus Therapeutics has published its Q3 2026 quarterly earnings report on November 10, 2026.
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at o...
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
LONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON and GAITHERSBURG, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Autolus Therapeutics (AUTL) with a Buy rating and $10 price target The firm says an approved CAR-T gives Autolus a “differentiated starting point” for autoimmune…
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics management to meet virtually with William Blair
Virtual Meeting to be held on September 24 hosted by William Blair.
Autolus Therapeutics Registration statement: Registration filing
Autolus Therapeutics filed a registration statement on September 14, 2026, providing details about a securities offering with the SEC.
Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders
06:06 EDT Autolus Therapeutics (AUTL) files to sell 3.5M American Depositary Shares for holders
Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel
Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleucel for the treatment of systemic lupus erythematosus...
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Slides: Corporate presentation
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Autolus Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth and margin expansion, driven by strong AUCATZYL sales and operational efficiencies. Guidance was raised, cash runway extended, and multiple clinical milestones are expected in 2027–2028.
Autolus Therapeutics Earnings release: Q2 2026
Autolus Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Autolus Therapeutics Slides: Q2 2026
Autolus Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Autolus Therapeutics Quarterly report: Q2 2026
Autolus Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.